Tiber Creek Health Strategies, INC. (on Behalf of Eli Lilly and Company)
Pharmaceutical company.
Based in DC
🤖
AI Overview
With $1.5M in lobbying spend across 22 quarterly filings, Tiber Creek Health Strategies, INC. (on Behalf of Eli Lilly and Company) is a significant lobbying presence.
$1.5M
Total Lobbying Spend
22
Quarterly Filings
1
Lobbying Firms Used
8
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2020 | $160K |
| 2021 | $180K |
| 2022 | $300K |
| 2023 | $320K |
| 2024 | $320K |
| 2025 | $240K |
Lobbying Firms
TIBER CREEK GROUP
What They Lobby For
- Issues related to drug pricing.
- Issues related to drug pricing. HR 6201 Families First Coronavirus Response Act (PL 116-27); CARES Act - S. 3548 (PL 116-136)
- CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act
- Issues related to non-immigrant visa restrictions
- Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; HR 4100/S 1712 DISARM Act; Executive Order on Lowering Drug Prices by Putting America First
- Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act; HR 4100/S 1712 DISARM Act; Executive Order on Lowering Drug Prices by Putting America First; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act; Issues related to the Medicaid Drug Rebate Program
- Issues relating to US intellectual property laws.
- Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Issues related to the American Families Plan; H.R. 2873 Affordable Prescriptions for Patients Through Promoting Competition Act; S.1435 Affordable Prescriptions for Patients Act of 2021.
- Issues related to the federal tax treatment of Global Intangible Low-Taxed Income (GILTI).
- H.R. 2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021; S.1435 - Affordable Prescriptions for Patients Act of 2021; H.R. 2891 - Preserve Access to Affordable Generics and Biosimilars Act.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
The 2025 Tariff Panic
As tariffs return, lobbying on trade surges.
Big Tech's $150M Lobbying War
Tech giants battle over AI, antitrust, privacy, and trade.
Who's Lobbying to Shape AI Policy
The AI regulation fight is the biggest lobbying battle of the decade.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.